Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Assessing drugs for ultra-rare conditions in the UK

Alexion’s Soliris has become the first drug to pass through NICE’s new highly specialised technology process

Bone Therapeutics looks to Pfizer for clinical head

Guy Heynen has 35 years of industry experience

- PMLiVE

BioCryst gets FDA nod for first intravenous flu drug

Expects to launch Rapivab in time for this year's flu season

- PMLiVE

EU approval for Lilly’s Cyramza in stomach cancer

Follows shortly after the drug's US approval in non-small cell lung cancer

- PMLiVE

Sovaldi dropped by Express Scripts in favour of Viekira Pak

Pharmacy benefits organisation ramps up US pricing pressure on Gilead

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

- PMLiVE

FDA backs Cubist’s antibiotic Zerbaxa

Combination cephalosporin and beta lactamase inhibitor wins US approval

The impending threat of antibiotic resistance

Antibiotic Research UK is the BIA's charity of 2015, but what does it intend to do?

Pharma’s pigeons

If it can adapt, a lucrative new niche is opening up for pharma

- PMLiVE

CRF Health boosts leadership team

John Blakely and Risto Enbuska join the electronic patient reported outcomes firm

- PMLiVE

AbbVie wins key approval for hep C pill Viekira Pak

Prices all-oral treatment fractionally lower than rivals from Gilead

Eli Lilly HQ

Lilly signs $570m deal for next-gen Humalog

Licenses improved version of its insulin blockbuster from Adocia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links